Cancer Screening

Objectives

Provide evidence-based, non-mandatory clinical guidance for cancer screening in Singapore, enabling clinicians and patients to select appropriate tests for asymptomatic people according to age, sex and individual risk. Screening is intended to improve prognosis and reduce cancer morbidity or mortality only where early detection, effective intervention and an acceptable balance of benefit, harm and cost are supported by evidence.[1][2][3][4]

• Apply screening as a continuing public-health process for important conditions with a recognisable early stage, suitable and acceptable tests, available diagnostic and treatment services, and an agreed policy on treatment following detection.[3]
• Cover nasopharyngeal, colorectal, liver, lung, breast, cervical, endometrial, ovarian and prostate cancers, while avoiding population screening where mortality benefit is unproven or harms outweigh likely benefits.[1][2][5][6]
• Screen average-risk adults for colorectal cancer from age 50, using faecal occult blood testing, preferably faecal immunochemical testing, or colonoscopy as principal population options; use colonoscopy and earlier surveillance for people at increased hereditary or clinical risk.[7][8][9][10]
• Improve early recognition of nasopharyngeal carcinoma through clinical awareness and targeted assessment, while not implementing general-population Epstein-Barr virus serology because mortality reduction has not been demonstrated.[11][12]
• Offer hepatocellular carcinoma surveillance to people with chronic hepatitis B infection or cirrhosis, using liver ultrasonography and serum alpha-fetoprotein testing at intervals based on risk.[13][14]
• Do not recommend routine lung-cancer screening outside clinical trials, as chest radiography, sputum cytology and low-dose computed tomography had not demonstrated a mortality benefit in the evidence considered.[14][15]
• Provide risk- and age-stratified breast screening: offer two-yearly mammography to normal-risk women aged 50 to 69, support informed annual screening choices for women aged 40 to 49, avoid imaging screening in normal-risk women under 40, and individualise decisions for older women according to health and life expectancy.[16][17]
• Detect cervical pre-malignant lesions through three-yearly Papanicolaou smear screening for women who have ever had sexual intercourse from age 25, including women vaccinated against human papillomavirus.[18][19][20]
• Restrict endometrial screening to women with or at risk of hereditary non-polyposis colorectal cancer, and do not routinely screen average-risk asymptomatic women for endometrial or ovarian cancer.[21][22][5]
• Do not support population-based prostate screening; instead, enable informed individual decisions for men likely to benefit, taking account of life expectancy, risk factors and the potential harms of overdiagnosis and treatment.[6][23][24]

Implementation

Deliver the guidance mainly through medical practitioners, particularly primary healthcare providers, who counsel patients, stratify risk, arrange testing and referrals, and apply recommendations to individual clinical circumstances. The Ministry of Health published the guideline, developed through a Ministry-appointed multidisciplinary workgroup including specialists, family practitioners and patient representatives, with input from professional organisations and consideration of Singapore population characteristics.[2][4][25][26]

• Base recommendations on reviews of research and international guidance, graded evidence ranging from high-quality randomised evidence to expert opinion, and recommendation grades from A to D or good-practice points.[4][27][28]
• Balance screening benefits against false-positive and false-negative findings, anxiety, unnecessary investigations, overdiagnosis, treatment harms, radiation exposure and procedure-related complications.[1][28][29][6]
• Use diagnostic confirmation after abnormal screening tests, including full colon examination after a positive faecal occult blood test, specialist assessment for suspected hepatocellular carcinoma, and biopsy where clinically indicated for nasopharyngeal or prostate cancer.[9][14][11][30]
• Refer people with suspected hereditary colorectal, breast or ovarian cancer risk to tertiary specialist or cancer genetics services for risk assessment, genetic testing and tailored surveillance.[10][31][32][5]
• Implement nationwide population-based cervical screening with collection of all Papanicolaou smear data, broad coverage and recall mechanisms; CervicalScreen Singapore is delivered by the Health Promotion Board for consenting women screened in polyclinics.[33][21]
• Support breast screening through opportunistic testing and systematic invitation programmes, including BreastScreen Singapore, and use mammography as the routine modality for normal-risk women rather than unproven imaging technologies.[34][16][35]
• Use shared decision-making for screening where benefit is uncertain or preference-sensitive, particularly mammography for women aged 40 to 49 and prostate-specific antigen testing, by explaining effectiveness, limitations, risks and costs.[36][16][23][37]
• Monitor national screening coverage against targets above 70% for mammography among women aged 50 to 69, cervical screening among women aged 25 to 69, and colorectal screening among people aged 50 to 69.[24]
• Set general-clinic targets above 90% for regular eligible patients receiving breast, cervical and colorectal screening, while recording inappropriate or non-recommended testing such as prostate-specific antigen testing in patients under 50.[38]
• Review the guideline five years after publication, or sooner when substantive new evidence warrants changes; individual recommendations may evolve as scientific knowledge and patterns of care change.[39][4]

Monitoring & Evaluation

Monitoring and evaluation rely principally on evidence grading, clinical quality indicators, screening uptake measures, test-performance data and scheduled guideline review. Recommendations are graded from A to D according to evidence levels ranging from high-quality randomised evidence to expert opinion, and the guidance is intended to be revised after five years or sooner if substantive new evidence emerges.[4][27][39]

• Assess screening policies against evidence from randomised controlled trials, cohort studies, case-control studies and uncontrolled clinical studies, including whether screening reduces morbidity or mortality and improves outcomes compared with non-screened populations.[28]
• Monitor clinical quality indicators and targets for national screening programmes and general clinic settings.[39]
• Track national screening coverage against targets above 70% for mammography among women aged 50 to 69 within two years, Papanicolaou smear screening among women aged 25 to 69 within three years, and colorectal screening among people aged 50 to 69 through faecal occult blood testing within one year or colonoscopy within 10 years.[24]
• Set clinic-level targets above 90% for regular eligible patients receiving breast, cervical and colorectal screening within the specified intervals; record prostate-specific antigen testing offered to people under 50 and the use of cancer antigen 125, carcinoembryonic antigen and lung-cancer screening without specified targets.[38]
• Collect data from all Papanicolaou smears through a proposed nationwide population-based cervical screening programme, supported by coverage and recall mechanisms.[33]
• Monitor breast-screening participation, frequency, sensitivity, specificity and interval cancers; a population mortality reduction is expected only after seven to ten years where 70% of the target population receives mammography.[34][40]
• Use surveillance intervals for hepatocellular carcinoma of six months for high-risk people and annually for other at-risk people, while recognising that the optimal starting age is not defined.[13][14]
• Continue prospective research on the effectiveness and cost-effectiveness of nasopharyngeal carcinoma screening among first-degree relatives, as mass screening has not demonstrated mortality reduction.[12]

Evidence limitations and potential harms are integral to accountability: recommendations caution that screening can yield false-positive and false-negative findings, overdiagnosis, unnecessary procedures and treatment harms, and that adherence does not guarantee successful outcomes.[4][1][29][6]Formal reporting arrangements, named monitoring bodies, comprehensive accountability structures and programme-wide evaluation timetables are otherwise not specified, apart from population data collection, stated indicators and the planned guideline review.[39][33][24][38]

Costing & Financing

The guidance addresses economic implications largely through qualitative cost-effectiveness considerations rather than a funded implementation plan. It does not specify programme budgets, funding allocations, financing mechanisms, funding sources, resource-mobilisation arrangements or funding gaps.[4][27][3]

• Balance the costs of case-finding, diagnosis and treatment of screen-detected disease against wider medical-care expenditure, and account for anxiety and further testing arising from false-positive results.[3][28]
• Use local decision models incorporating colorectal cancer incidence, natural history, screening and treatment costs, and test sensitivity and specificity; Singapore modelling found screening could increase life expectancy among people aged 50 to 70.[10][36]
• Recognise faecal occult blood testing as the most cost-effective colorectal population-screening method against no screening in one comparison, while colonoscopy became more cost-effective when compliance was considered.[36]
• Consider high costs as a constraint on stool DNA testing and recognise that repeated computed tomographic colonography carries cumulative radiation exposure as well as resource implications.[41]
• Recognise higher costs and false-positive rates for mammography in women aged 40 to 49; the cost per life-year saved is estimated to be approximately five times that for women over 50, and magnetic resonance imaging costs substantially more than conventional breast imaging.[34][29][35]
• Recognise that liquid-based cervical cytology costs more than conventional cytology, although fewer repeat tests for inadequate samples and improved laboratory productivity may partly offset this.[33]
• Note that organised cervical screening is associated with lower mortality and costs than opportunistic screening, with Hong Kong evidence finding opportunistic approaches more costly and less effective than organised screening at three-, four- or five-year intervals.[21]
• Interpret prostate-screening estimates cautiously: published cost-effectiveness estimates range from United States dollars 14,000 to 66,000 per quality-adjusted life-year, and individualised re-screening intervals may improve cost-effectiveness.[37]

Further economic evaluation is specifically needed for formal screening of asymptomatic first-degree relatives of people with nasopharyngeal carcinoma. Economic findings from Western breast-screening populations may not transfer directly to Singapore because local breast-cancer incidence is lower.[12][35]